Cempra (NASDAQ:CEMP) is a clinical-stage pharmaceutical company focused on developing antibacterials to meet clinical needs. The company has two lead antibacterial products to address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in both the hospital and community. The World Health Organization has stated that antibiotic resistance is one of the greatest healthcare challenges for the future. Cempra has two antibiotic candidates, solithromycin (CEM-101) and TAKSTA (CEM-102, sodium fusidate), in late-stage clinical trials.
